Next Article in Journal
Nociceptive TRP Channels: Sensory Detectors and Transducers in Multiple Pain Pathologies
Previous Article in Journal
Blocking TRPA1 in Respiratory Disorders: Does It Hold a Promise?
Previous Article in Special Issue
Chemical Variations on the p53 Reactivation Theme
Open AccessFeature PaperReview

Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives

i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, IPATIMUP, 4200-465 Porto, Portugal
ICBAS-UP-Institute of Biomedical Sciences Abel Salazar, University of Porto, ICBAS-UP, 4099-003 Porto, Portugal
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
CIIMAR/CIMAR-Interdisciplinary Centre of Marine and Environmental Research, University of Porto, 4050-123 Porto, Portugal
Laboratory of Microbiology, Department of Biological Sciences, FFUP-Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Pharmaceuticals 2016, 9(4), 71;
Received: 18 August 2016 / Revised: 2 November 2016 / Accepted: 2 November 2016 / Published: 10 November 2016
Multidrug resistance (MDR) presents a serious challenge to the efficiency of cancer treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, due to toxicity problems, drug interactions, or pharmacokinetic issues. Therefore, it is important to identify novel inhibitors of P-gp activity or expression. Curcumin is a secondary metabolite isolated from the turmeric of Curcuma longa L. which has been associated with several biological activities, particularly P-gp modulatory activity (by inhibiting both P-gp function and expression). However, curcumin shows extensive metabolism and instability, which has justified the recent and intensive search for analogs of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This review summarizes and compares the effects of curcumin and several curcumin analogs on P-glycoprotein function and expression, emphasizing the potential of these molecules for the possible development of safe and effective inhibitors of P-gp to overcome MDR in human cancer. View Full-Text
Keywords: P-glycoprotein; multidrug resistance; curcumin; curcumin analogs P-glycoprotein; multidrug resistance; curcumin; curcumin analogs
Show Figures

Figure 1

MDPI and ACS Style

Lopes-Rodrigues, V.; Sousa, E.; Vasconcelos, M.H. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals 2016, 9, 71.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop